{"id":15946,"date":"2023-07-21T23:40:00","date_gmt":"2023-07-21T15:40:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15946"},"modified":"2024-11-30T23:49:18","modified_gmt":"2024-11-30T15:49:18","slug":"riparian-pharmaceuticals-secures-exclusive-license-agreement-with-pfizer-for-cardiovascular-program","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15946","title":{"rendered":"Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program"},"content":{"rendered":"\n

US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva Biotech (HKG: 1873<\/a>), has announced an exclusive license agreement and research agreement with US pharmaceutical giant Pfizer (NYSE: PFE<\/a>). Under the terms of the agreement, Pfizer will receive exclusive rights to a Riparian preclinical program in exchange for upfront and milestone payments, as well as royalties on sales of any resulting therapeutics.<\/p>\n\n\n\n

Supporting Riparian’s Vasoprotection Efforts<\/strong>
As part of the research agreement, Pfizer will provide support for Riparian\u2019s ongoing efforts to discover further drug targets that lead to vasoprotection, a process aimed at protecting blood vessels from damage. Pfizer will also have an option on such targets, indicating a strategic commitment to advancing cardiovascular therapies.<\/p>\n\n\n\n

Funding and Partnerships for Riparian Pharmaceuticals<\/strong>
Riparian Pharmaceuticals, a privately held biotech company dedicated to discovering drug targets and therapeutics that address endothelial dysfunction and vascular inflammation, has secured USD 6 million in combined investment and research services from Viva Biotech Incubator and JMCR Partners. Additionally, the company has received support from research foundations such as the National Institutes of Health and the Massachusetts Life Science Center, highlighting the significance of its work in the field of cardiovascular diseases.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[69,1353,863,309,2507,1352],"class_list":["post-15946","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cvd","tag-hkg-1873","tag-nyse-pfe","tag-pfizer","tag-riparian-pharmaceuticals","tag-viva-biotech"],"yoast_head":"\nRiparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva Biotech (HKG: 1873), has announced an exclusive license agreement and research agreement with US pharmaceutical giant Pfizer (NYSE: PFE). Under the terms of the agreement, Pfizer will receive exclusive rights to a Riparian preclinical program in exchange for upfront and milestone payments, as well as royalties on sales of any resulting therapeutics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15946\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15946\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-21T15:40:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-30T15:49:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15946#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15946\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program\",\"datePublished\":\"2023-07-21T15:40:00+00:00\",\"dateModified\":\"2024-11-30T15:49:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15946\"},\"wordCount\":214,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CVD\",\"HKG: 1873\",\"NYSE: PFE\",\"Pfizer\",\"Riparian Pharmaceuticals\",\"VIVA Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15946#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15946\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15946\",\"name\":\"Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-21T15:40:00+00:00\",\"dateModified\":\"2024-11-30T15:49:18+00:00\",\"description\":\"US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva Biotech (HKG: 1873), has announced an exclusive license agreement and research agreement with US pharmaceutical giant Pfizer (NYSE: PFE). Under the terms of the agreement, Pfizer will receive exclusive rights to a Riparian preclinical program in exchange for upfront and milestone payments, as well as royalties on sales of any resulting therapeutics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15946#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15946\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15946#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program - Insight, China's Pharmaceutical Industry","description":"US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva Biotech (HKG: 1873), has announced an exclusive license agreement and research agreement with US pharmaceutical giant Pfizer (NYSE: PFE). Under the terms of the agreement, Pfizer will receive exclusive rights to a Riparian preclinical program in exchange for upfront and milestone payments, as well as royalties on sales of any resulting therapeutics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15946","og_locale":"en_US","og_type":"article","og_title":"Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15946","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-21T15:40:00+00:00","article_modified_time":"2024-11-30T15:49:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15946#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15946"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program","datePublished":"2023-07-21T15:40:00+00:00","dateModified":"2024-11-30T15:49:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15946"},"wordCount":214,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CVD","HKG: 1873","NYSE: PFE","Pfizer","Riparian Pharmaceuticals","VIVA Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15946#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15946","url":"https:\/\/flcube.com\/?p=15946","name":"Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-21T15:40:00+00:00","dateModified":"2024-11-30T15:49:18+00:00","description":"US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva Biotech (HKG: 1873), has announced an exclusive license agreement and research agreement with US pharmaceutical giant Pfizer (NYSE: PFE). Under the terms of the agreement, Pfizer will receive exclusive rights to a Riparian preclinical program in exchange for upfront and milestone payments, as well as royalties on sales of any resulting therapeutics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15946#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15946"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15946#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15946"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15946\/revisions"}],"predecessor-version":[{"id":15949,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15946\/revisions\/15949"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}